Introduction
Gabapentin (GBP), a structural analog of g-aminobutyric acid, was initially used as an anticonvulsant and antinociceptive drug [1] . Its exact mechanism of action is unknown but GBP is thought to bind to the a2d subunit of voltage-dependent calcium channels [2] . More recently, GBP has been used extensively for the treatment of acute postsurgical pain, in part due to a mild adverse effect profile which includes (% patients): somnolence (20%), dizziness (18%), ataxia (13%), and fatigue (11%) [3] . GBP has been found to be an effective perioperative analgesic following abdominal or pelvic surgery [4] [5] [6] , musculoskeletal surgery [7] [8] [9] , head and neck surgery [10, 11] , breast surgery [12] [13] [14] , varicocele surgery [15] , and thoracic surgery [16] . Several meta-analyses have confirmed the efficacy of GBP in reducing postoperative opioid use and pain scores [17] [18] [19] . GBP has also been found to be efficacious in the treatment of various psychiatric disorders such as social anxiety disorder [20] , bipolar disorder [21] , and posttraumatic stress disorder [22, 23] . In recent years, GBP has become a frontline drug in the treatment of chemical addiction [24] as evidenced by its ability to diminish addiction-seeking behaviors [25] .
Preoperative anxiety is a major concern for a subset of patients undergoing surgery. Intense preoperative anxiety and fear-based states have been shown to be associated with [1] higher intensity of acute postoperative pain and greater analgesic consumption [26] , as well as [2] the development of chronic postsurgical pain [27] [28] [29] . The efficacy of benzodiazepines for the treatment of preoperative anxiolysis in adults and children has been well documented [30, 31] . Novel anti-anxiety techniques/ agents continue to be investigated for the pediatric population [32, 33] . Until recently, there have been very few studies examining alternative pharmacologic interventions for the treatment of preoperative adult anxiety. GBP is used "off-label" for the treatment of preoperative anxiety.
The efficacy of using GBP for the treatment of preoperative anxiety in patients who are unable to tolerate benzodiazepines deserves further study. A recent study demonstrated that preoperative anxiety was significantly lower in patients given GBP vs placebo prior to anterior cruciate ligament repair [34] . However, predrug baseline anxiety scores were not measured, raising concern about the veracity of the observation. In another study, GBP was less effective in reducing preoperative anxiety when compared with an active placebo (15 mg of oxazepam) in patients undergoing vaginal hysterectomy [5] . However, these authors also did not report predrug baseline anxiety scores. In a recent study by White and colleagues, pregabalin (75-300 mg po), a newer a2d subunit voltagedependent calcium channel blocker, increased perioperative sedation in a dose-related fashion, but failed to reduce preoperative state anxiety when given preoperatively [35] . Using a dental anxiety model, 150 mg of pregabalin recently demonstrated good anxiolytic efficacy when compared with controls; however, patients experienced increased somnolence [36] .
Given the mixed results, we tested the hypothesis that GBP reduces preoperative anxiety. Using novel data collected within a double blinded randomized placebo controlled trial [37] , we examined whether the preoperative administration of 600 mg of GBP vs an identical placebo capsule decreased preoperative anxiety in patients scheduled for total hip arthroplasty under spinal anesthesia. The design of the original trial consisted of three treatment groups: Group 1 (placebo/placebo); Group 2 (GBP 600mg/placebo); and Group 3: (placebo/GBP 600mg) (i.e., treatment received 2 hours prior to surgery/treatment received in the postoperative anesthetic care area) [37] . Only Group 2 received GBP 2 hours prior to surgery; therefore, anxiety data from Groups 1 and 3 were combined for the placebo group in this manuscript.
Methods
This study was approved by the Research Ethics Board of the Sunnybrook Health Sciences Centre, and all patients gave informed, written consent to participate. Patients between the ages of 18-75 with an American Society of Anesthesiologists (ASA) physical status score of I, II, or III undergoing total hip arthroplasty were eligible for this study. Patients were not eligible if they had a known allergy to any of the medications being used, a history of drug or alcohol abuse, a history of being on chronic pain medications (i.e., slow-release preparations of opioids), rheumatoid arthritis, a psychiatric disorder, a history of diabetes with impaired renal function, a body mass index of greater than 45, or patients unable or unwilling to use patientcontrolled analgesia. Patients were identified and recruited at their preoperative anesthesia assessment visit approximately 1-2 weeks in advance of their surgery. All subjects were screened and the study protocol, along with the use of the visual analog anxiety scale (VAS) a 100-mm scale (with endpoints labeled "No anxiety" and "Extreme Anxiety") were explained at the time of enrollment.
The present sample comprised 70 patients who participated in a double blind, randomized, controlled trial in which all patients received acetaminophen 1 g po and celecoxib 400 mg po 2 hours preoperatively [37] . The primary foci of the study were the effects of GBP on anxiety, postoperative pain and opioid consumption. Patients were randomly assigned to one of the three treatment groups (before/after anesthesia): Group 1: Placebo/ Placebo (N = 24); Group 2: GBP/Placebo (N = 22); Group 3: Placebo/GBP (N = 24). Group 2 received GBP 600 mg po 2 hours prior to surgery; the other groups received an identically looking placebo capsule. Prior to the administration of the preoperative medications in the presurgical waiting area, all patients were asked to rate their baseline anxiety level prior to surgery on a 100-mm VAS. This VAS was similar to the scale used by Menigaux and colleagues [34] . Upon arrival to the regional anesthesia care area (2 hours after the ingestion of GBP or placebo), patients were asked by a nurse to again rate their current level of anxiety using an identical 100-mm VAS.
Statistical Power
The present study has sufficient power for the detection of an effect equivalent to a 25% reduction in baseline anxiety scores in the treatment group when compared with controls. Given our sample size (N = 48 for the controls and N = 22 for the treatment group) and under the assumption that the coefficient of variation of the control group is equal to 0.3, the current study has 96.3% power to detect a significant decrease in baseline anxiety. The above assumptions are based on the results found in the Menigaux study. That study had a total of 40 patients (N = 20 patients per group) and demonstrated that preoperative VAS anxiety scores were significantly lower in the GBP group than in the control group (28 Ϯ 16 vs 66 Ϯ 15 mm, respectively; P = 0.0001) [34] .
Statistical Analysis
Age, gender, body mass index, and ASA status, as well as baseline and preoperative anxiety scores were compared between patients who received GBP (Group 2, N = 22) or placebo (Groups 1 and 3, N = 48), using the nonparametric Wilcoxon test (for continuous data) and Fisher's exact test (for categorical data). A nonparametric test was used for the continuous variables because their distributions deviated from the normal.
To reduce any bias in postdrug anxiety scores introduced by potential differences in the baseline (predrug) anxiety scores, an analysis of covariance (ANCOVA) model was fitted, using the baseline (predrug) anxiety scores as the covariate [38] . The ANCOVA model used the postdrug ingestion anxiety score as a continuous outcome, the treatment group as a factor and the baseline anxiety score as a continuous covariate. The model tested whether GBP administration had any effect on the postdrug anxiety scores after adjusting for the variance in baseline anxiety scores.
Anxiety: Postoperative Pain and Opioid Consumption
The nonparametric Spearman's rank correlation was used to test for an association between anxiety (baseline or preoperative) and the following postoperative variables; maximal pain at rest, maximal pain with movement, and cumulative morphine consumption at 48 hours.
Results
The two groups were comparable with respect to age, gender, BMI, ASA status, predrug baseline anxiety scores, and postdrug anxiety scores (Table 1) . A significant difference was not found in postdrug anxiety scores between GBP-and placebo-treated patients after adjusting for baseline anxiety scores (Table 2) . Theses results demonstrate that anxiety scores were not different after treatment with GBP or placebo, regardless of patients' baseline level of anxiety. Table 3 shows the correlation coefficients between anxiety scores (predrug and postdrug) and acute postoperative endpoints. Baseline predrug anxiety and postdrug anxiety failed to demonstrate a significant association with any of the postoperative variables; maximal pain at rest, maximal pain with movement, and cumulative morphine consumption 48 hours after surgery (Table 3) .
Discussion
These results indicate that GBP 600 mg did not produce anxiolysis compared with placebo when administered 2 Significant between group differences in preoperative anxiety scores were not observed after controlling for baseline anxiety levels.
hours prior to total hip arthroplasty. These results contrast with those of a previous study in which preoperative anxiety scores were reported to be lower in patients who received GBP 1200 mg [34] and are congruent with the results by White and colleagues with respect to pregabalin and preoperative anxiety [35] . However, unlike in the present study, Menigaux et al. did not obtain a baseline (predrug) measure of anxiety prior to the administration of the GBP, raising the possibility that the observed differences in anxiety reported after GBP reflect pre-existing baseline differences that went undetected. The same criticism can be made of the Rorarius trial which reported that active placebo (i.e., patients receiving oxazepam 15 mg) were less anxious than those in the GBP group (1200 mg) upon arrival to the operating room theater [5] . Once again, there was a lack of baseline anxiety data.
Many of the perioperative trials reported thus far, suggest that a single dose of 1200 mg of GBP orally administered prior to surgery is safe and has only minor side effects [9, 12, 39] . However, a body of evidence has emerged which points to the need for added vigilance when using GBP in the elderly and in patients with significantly compromised renal function [40] [41] [42] [43] [44] . It is possible that the GBP dose used in our trial was too low to demonstrate a significant anxiolytic effect. The rationale for choosing the 600 mg dose of GBP was the following: 1) GBP administration at doses greater than 600 mg preoperatively have demonstrated increased side effects such as dizziness, sedation, and ataxia without any further benefit with respect to analgesia [8] ; 2) preoperative administration of 600 mg of GBP is routinely used for multimodal perioperative regimens, in which regional anesthesia is used as the main anesthetic modality, for lower limb arthroplasty [7, 37] ; and 3) patients undergoing total joint arthroplasty are significantly older than previously studied cohorts which increases patient vulnerability to the side effects of GBP. Given that early rehabilitation is one of the most important endpoints after total joint arthroplasty, the prevention of side effects that might have impaired patient physical functioning on postoperative day 1 was a major factor in the choice of adding the 600 mg of GBP to our perioperative pain regimen. Finally, sedation, drowsiness and dizziness that tend to occur at the higher initial drug doses may well have confounded the assessment of anxiolysis [4, 8, 36, 45] . Differences were not observed with respect to sedation, dizziness, and ataxia between the two groups at any point in this trial [37] .
Although advances in anesthesia and surgical techniques continue to evolve at a rapid rate, the treatment of adult preoperative anxiety has remained relatively constant over the past decade. Benzodiazepines remain the drug of choice for the treatment of preoperative anxiety. Alternative treatments should continue to be investigated for the subset of patients that may be unable to tolerate this medication (i.e., an allergic response or recovering from physical dependence/addiction to the medication). A head to head comparison with respect to benzodiazepines is warranted. Further well-controlled and well designed studies are needed before GBP can be recommended for the "off-label" treatment of preoperative anxiety. 
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